WASHINGTON — TrumpRx, the White House-backed prescription drug discount portal, still lists around one-third of its medicines above prices paid in the United Kingdom even after steep advertised cuts on obesity and fertility treatments, according to a Reuters comparison of 54 live TrumpRx listings and UK government prices. The gap matters because the administration has promoted the site as proof that Americans are finally getting most-favored-nation pricing, but the early savings appear uneven and concentrated in categories that matter most to people paying cash rather than patients using insurance, March 19, 2026.
Why TrumpRx drug prices still trail British benchmarks
Reuters found U.K. prices were lower for roughly a third of the medicines then listed on TrumpRx, including Pfizer’s Xeljanz, AstraZeneca’s Farxiga and GSK inhalers, which were 67% to 82% cheaper in Britain. The comparison was not a simple retail-to-retail checkout test: it matched TrumpRx cash prices against what U.K. pharmacies are paid by the NHS, making it more useful as a policy benchmark than as a pharmacy-counter apples-to-apples comparison.
That is what makes the result notable. Britain’s own December 2025 pharmaceuticals deal with Washington committed the United Kingdom to invest about 25% more in innovative medicines while preserving tariff-free access to the U.S. market. Even after that shift, a meaningful slice of TrumpRx’s live offers still did not beat British benchmark pricing.
Where TrumpRx drug prices are falling fastest
The administration’s Feb. 5 launch fact sheet described TrumpRx as a first-wave rollout covering 40 branded medicines from five manufacturers, with the biggest advertised cuts concentrated in GLP-1 and fertility products. Those categories remain the portal’s clearest success story because they often leave patients with high out-of-pocket costs even when insurance exists.
The live TrumpRx site still highlights blockbuster examples such as Wegovy, Ozempic and Zepbound at sharply lower starting prices than their U.S. list prices. That helps explain how the portal can deliver genuine savings on high-profile drugs while still falling short of the broader claim that it now offers the lowest prices in the world across its full catalog.
Why TrumpRx drug prices may not reshape most pharmacy bills
Reuters reported at launch that TrumpRx is not a conventional storefront. In most cases it routes users to a manufacturer-run purchase page or provides a coupon, which means the headline discounts mostly apply to cash-paying patients and do not automatically change what insured patients owe through their health plans.
That limitation matters. A portal can cap some direct-to-consumer prices and still leave the wider U.S. system mostly intact, because the bigger pricing battles run through insurers, pharmacy benefit managers, Medicare and Medicaid formularies, and negotiated rebates that the TrumpRx checkout flow does not directly rewrite.
TrumpRx drug prices fit a much longer political push
The policy line did not begin with this website. Reuters reported in November 2020 that the first Trump administration planned a most-favored-nation rule tying some Medicare payments to prices in other wealthy countries, and another Reuters report later that year said a federal judge blocked the rule.
The idea returned in July 2025, when Reuters reported that Trump had pressed 17 pharmaceutical CEOs to match the lowest price offered in developed nations. By December, Reuters reported that nine drugmakers had agreed to Medicaid and cash-pay cuts ahead of the TrumpRx debut.
The bottom line is that TrumpRx has plainly created visible discounts on some high-profile medicines, especially GLP-1 and fertility drugs. But the latest Reuters comparison shows the headline claim still outruns the evidence: for roughly one-third of listed medicines, British prices remain lower.
